#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2814	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2338	331.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1542	1542	C	343	C	263	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2814	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2338	331.6	0	HET	.	.	.	C481T	.	481	481	C	839	839	C	402	C,T	235,92	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5034	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	346.8	0	.	n	.	0	T695C	SNP	695	695	T	1259	1259	C	405	C,T	329,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5034	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	346.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1901	1901	A	422	A	340	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5034	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	346.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2535	2535	C	366	C,A	292,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5034	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	346.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2609	2609	A	383	A	310	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5034	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	346.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3161	3161	C	426	C	346	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	27	12270	blaTEM	861	861	100.0	blaTEM.l15.c4.ctg.1	1910	1779.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	408	folP	855	855	99.88	folP.l15.c4.ctg.1	1920	59.3	1	SNP	p	R229S	1	R229S	NONSYN	685	687	CGC	1150	1152	AGC	72;70;70	A;G;C	64;62;58	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	539	1062	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3936	74.7	0	.	p	.	0	G95A	NONSYN	283	285	GGC	824	826	GCC	93;93;94	G;C;C	75;76;76	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	539	1062	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3936	74.7	1	SNP	p	S91F	1	.	.	271	273	TTC	812	814	TTC	94;94;93	T;T;C	74;73;74	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	498	mtrR	633	633	100.0	mtrR.l6.c17.ctg.1	1496	92.0	1	SNP	p	G45D	0	.	.	133	135	GGC	555	557	GGC	120;118;117	G;G;C,T	99;96;95,1	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	278	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1318	58.3	0	.	n	.	0	A197.	DEL	197	197	A	686	686	A	108	A	90	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	912	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3423	75.9	1	SNP	p	D86N	0	.	.	256	258	GAC	797	799	GAC	88;87;87	G;A;C	68;66;67	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	912	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3423	75.9	1	SNP	p	S88P	0	.	.	262	264	TCC	803	805	TCC	88;86;86	T;C;C	69;69;69	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	788	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3252	68.6	0	.	p	.	0	P456S	NONSYN	1366	1368	CCC	2007	2009	TCC	84;86;86	T;C;C	68;71;72	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	788	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3252	68.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1869	1871	GGC	101;101;100	G;G;C	76;79;75	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1501	1503	GCA	95;95;97	G;C;A,C	78;75;76,1	penA.43.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1504	1506	ATC	97;96;98	A;T;C	78;76;80	penA.43.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1516	1518	GTG	99;99;99	G;T,G;G	78;74,1;81	penA.43.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1516	1518	GTG	99;99;99	G;T,G;G	78;74,1;81	penA.43.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2020	2022	ACC	64;65;65	A;C;C	54;55;58	penA.43.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2074	2076	GTG	64;63;64	G;T,G;G	49;43,3;43	penA.43.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2074	2076	GTG	64;63;64	G;T,G;G	49;43,3;43	penA.43.002:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2197	2199	GGC	77;77;78	G,C;G;C	62,1;62;63	penA.43.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2206	2208	GGC	78;78;78	G;G;C	63;64;63	penA.43.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	27	706	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2859	68.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2224	2226	CCG	78;78;77	C,T;C;G	57,2;60;57	penA.43.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	868	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3512	69.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1805	1807	CCG	42;42;42	C;C;G,C	32;34;34,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	506	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2432	58.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	665	667	GGC	85;85;86	G,A;G;C	74,1;73;73	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	506	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2432	58.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	847	847	C	69	C,G	56,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	620	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1728	96.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	531	533	GAA	121;125;124	G,A;A;A	92,1;97;99	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	620	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1728	96.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	942	944	TCA	108;110;110	T;C;A	87;90;89	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	620	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1728	96.0	0	.	p	.	0	A218I	NONSYN	652	654	GCC	1071	1073	ATC	107;107;109	A;T,A;C	90;86,2;87	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	620	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1728	96.0	1	SNP	p	G120K	1	.	.	358	360	AAG	777	779	AAG	106;105;105	A;A;G	84;87;83	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	620	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1728	96.0	1	SNP	p	D121N	0	.	.	361	363	GAC	780	782	GAC	103;103;103	G;A;C,A	86;84;82,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	620	porB1b	1047	1047	99.43	porB1b.l15.c30.ctg.1	1728	96.0	1	SNP	p	A121D	1	.	.	361	363	GAC	780	782	GAC	103;103;103	G;A;C,A	86;84;82,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1896	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5394	98.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	330	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1426	65.5	1	SNP	p	V57M	1	.	.	169	171	ATG	762	764	ATG	130;129;130	A;T;G	108;110;101	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	1598	tetM	1920	1920	100.0	tetM.l6.c17.ctg.1	3008	149.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
